TME Pharma N.V. (EPA:ALTME)

France flag France · Delayed Price · Currency is EUR
0.0754
-0.0036 (-4.56%)
Apr 29, 2026, 9:22 AM CET
17.08%
Market Cap 7.43M
Revenue (ttm) 27.00K
Net Income (ttm) -4.58M
Shares Out 94.09M
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 30,079
Average Volume 376,420
Open 0.0798
Previous Close 0.0790
Day's Range 0.0730 - 0.0798
52-Week Range 0.0490 - 0.1480
Beta 0.57
RSI 57.62
Earnings Date Apr 30, 2026

About TME Pharma

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company’s Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2a clinical trial for the treatme... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 12
Stock Exchange Euronext Paris
Ticker Symbol ALTME
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.